GALMED PHARMACEUTICALS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3895 USD | -2.04% |
|
-3.52% | -14.40% |
Presentation Operator MessageOperator (Operator)Good day and welcome to Galmed's Fourth Quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Calendar
2025-05-06
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3895
USD
Average target price
1
USD
Spread / Average Target
+156.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.40% | 2.39M | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- GLMD Stock
- News Galmed Pharmaceuticals Ltd.
- Transcript : Galmed Pharmaceuticals Ltd., Q4 2019 Earnings Call, Mar 12, 2020